Overview

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
Phase:
PHASE2
Details
Lead Sponsor:
Jasper Therapeutics, Inc.